Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional profiling of liver obtained from a mouse model for metabolic dysfunction-associated steatotic liver disease

ABSTRACT: Transcriptional profiling of liver obtained from a mouse model for metabolic dysfunction-associated steatotic liver disease

PROVIDER: PRJNA1173164 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31001965_1.fastq.gz	Fastqsanger.gz
	SRR31001965_2.fastq.gz	Fastqsanger.gz
	SRR31001966_1.fastq.gz	Fastqsanger.gz
	SRR31001966_2.fastq.gz	Fastqsanger.gz
	SRR31001967_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Liver TET1 promotes metabolic dysfunction-associated steatotic liver disease

Project description:Liver TET1 promotes metabolic dysfunction-associated steatotic liver disease

| PRJNA1209064 | ENA

Transcriptional profiling of liver obtained from a mouse model for metabolic dysfunction-associated steatotic liver disease

Project description:Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent hepatic disorder worldwide and closely associated with type 2 diabetes mellitus (T2DM). The pathogenesis of MASLD is multifaceted and its treatment options are very limited. Consequently, it is urgent to identify novel therapeutic targets and develop effective treatment strategies. RNA sequencing analysis was performed to understand the transcriptomic changes in a mouse model of MASLD.

2025-01-20 | GSE279512 | GEO

Oxidised apolipoprotein peptidome characterise metabolic dysfunction-associated steatotic liver disease.Oxidised apolipoprotein peptidome characterise metabolic dysfunction-associated steatotic liver disease.

Project description:A proteomic and peptidomics analysis of serum from patients suffering from metabolic dysfunction-associated steatotic liver disease. Proteomics was performed initially on a set of patients with varying degrees of liver disease. Following close analysis of the results, a peptidomics based analysis was performed and identified significant numbers of degraded and oxidised peptides from apolipoproteins. A more targeted peptidomics analysis was performed on a larger cohort and the oxidation status of small apolipoproteins demonstrated a high accuracy of precision for liver disease diagnosis.

2025-01-21 | PXD052061 | Pride

RNA-seq data of primary human hepatocytes spheroids from healthy and Metabolic dysfunction associated steatotic liver disease (MASLD) donors following troglitazone treatment

Project description:Primary human hepatocytes from healthy and Metabolic dysfunction associated steatotic liver disease (MASLD) patients (6 donors each) as 3D spheroids treated with troglitazone (3 concentrations, 0.1xCmax, Cmax and 10xCmax) and vehicle for 7 h. Data for Figure 5 in connected publication.

2026-01-16 | E-MTAB-15610 | biostudies-arrayexpress

Deep proteome profiling of metabolic dysfunction-associated steatotic liver disease

Project description:Analyze human biopsies for the investigation of metabolic dysfunction-associated steatotic liver disease (MASLD). We also analyzed plasma samples for biomarker discovery. And analyzed the role of the impact of the adipose tissue on plasma proteins in relation to MASLD

2025-03-05 | PXD051911 | Pride

Spatial transcriptome profile of liver tissue from a patient with metabolic dysfunction-associated steatotic liver disease

Project description:Metabolic dysfunction-associated steatotic liver disease (MASLD) causes progressive liver fibrosis and hepatocellular carcinoma (HCC). By using archived fixed surgical liver tissue affected with MASLD, we performed Visium Spatial Transcriptome profiling to study spatially-resolved moelcular dysregulatons associated with the clinical phenotypes of the disease and mechanisms of liver fibrogenesis and carcinogenesis.

2026-07-22 | GSE278621 | GEO

Transcriptomic profiles of liver biopsies in obese patients with metabolic dysfunction-associated steatotic liver disease

Project description:The molecular mechanisms underlying early-stage metabolic dysfunction-associated steatotic liver disease (MASLD) is poorly understood. This study characterized the transcriptomic alterations in obese patients with no pathology or early-stage MASLD. 94 snap-frozen liver biopsies were analyzed through high-throughput RNA sequencing. Distinct features involved in the development of hepatic steatosis and fibrosis were identified. This study also provided novel insights in mechanisms involved in the onset of fibrosis, highlighting potential therapeutic targets.

2025-12-10 | GSE281797 | GEO

Single nucleus chromatin accessibility Profiling on the human metabolic dysfunction associated steatotic liver disease samples

Project description:Single-nucleus Assay for Transposase-Accessible Chromatin with sequencing (snATAC-seq) in human mapping of chromatin accessibility in specific cell clusters profiled alterations in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) samples compared to normal controls, providing insights into cell-type-specific epigenetic changes associated with MASLD.

2026-03-16 | GSE281367 | GEO

Hepatic miR-93 promotes the pathogenesis of metabolic dysfunction-associated steatotic liver disease by suppressing SIRT1

Project description:The molecular mechanisms underlying the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD) remain largely unclear. Emerging evidence suggests that microRNAs (miRNAs) play a critical role in transcriptional regulation by targeting genes involved in MASLD and other metabolic disorders, this study aims to elucidate the role of miR-93 in lipid metabolism and its impact on MASLD progression.

2025-04-14 | GSE277560 | GEO

Untargeted proteomic analysis of simultaneously collected human liver tissue and plasma of patients with a histological diagnosis of metabolic dysfunction-associated steatotic liver disease.

Project description:The liver tissue and plasma were collected from patients when undergoing liver biopsy for a diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD), along with controls who had no histological abnormalities. The study group included seven patients with no liver histological abnormalities and 64 patients with MASLD across its spectrum, including those with metabolic dysfunction-associated steatotic hepatitis (MASH) and those with cirrhosis. The data were compared between liver tissue and plasma, across various stages of MASLD, and for the detection of biomarkers for different stages of MASLD.

2024-06-07 | MSV000094959 | MassIVE

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data